Tag: Diabetes: Type II
Greater Awareness Needed for Potential of T2DM Remission
Two test results below the diagnostic threshold, two months apart, can confirm remission
Exenatide Doesn’t Up Cardiovascular Risk in T2DM
Exenatide found to be non-inferior to placebo with respect to safety for patients with type 2 diabetes
2017 Standards of Medical Care in Diabetes Released
Recommendations for T1D focus on monitoring, pharmacologic approaches to glycemic management
Biomarkers Can Predict Rapid Drop in Renal Function in T2DM
ApoA4, CD5L, C1QB, IBP3 may improve prediction of rapid decline in renal function in type 2 diabetes
Liraglutide Tied to Reduced Progression of Diabetic Kidney Dz
Prespecified secondary analysis shows benefit for liraglutide when added to usual care in T2DM
Higher Event Rate of T2DM in Polycystic Ovary Syndrome
Diagnosis of type 2 diabetes at a younger age in women with PCOS versus age-matched controls
Novel Genetic Variant in IGF2 Linked to Reduced T2DM Risk
Variant is associated with allele-dosage dependent reduction in IGF2 isoform 2 expression
Fatty Acid Remodeling Seen in T2DM Remission Post Bariatric Sx
Triglyceride disposal and acylcarnitine production during lipid overload improved with weight loss
Diacerein Reduces Mean Hemoglobin A1c Levels in T2DM
Peak of effect occurred at 24th week of treatment; attenuated toward nonsignificance at 48th week
No Increase in Acute Kidney Injury Risk for SGLT2 Users
Using data from two health systems, no increased risk seen in AKI, even after adjustment for covariates
